Licensing and collaboration
Vectura seeks out-licensing partners for its development products usually at the completion of Phase II trials. Partners should be able to contribute to the later-stage development and/or commercialisation of the product with demonstrable expertise, and to maximise the exploitation of the product in the marketplace. Vectura is happy to consider global and territorially based licensing deals.
Vectura is currently seeking to partner its products: VR040 for Parkinson's disease, VR147 for migraine, VR004 for erectile dysfunction and VR776 for premature ejaculation, as well as its inhaled insulin product.
Vectura will continue to grow its product pipeline through development of its own inventions but also through in-licensing or co-development of new opportunities. Vectura is actively seeking such opportunities in the areas of respiratory disease and neurology, with an emphasis on projects that are at the clinical stage.
Vectura's proprietary device and formulation technologies, GyroHaler®, OmniHaler®, Aspirair® , Clickhaler®, Duohaler®, Unit Dose DPIs, PowderHale® and other formulation technologies underpin its product pipeline. Vectura also licenses these technologies on a non-exclusive basis to other pharmaceutical companies where the resulting programme will complement Vectura's overall business strategy and commercial returns. Vectura is actively seeking partners and is able to support such licensing deals with formulation and device development expertise as part of a wider development collaboration.
To discuss licensing or collaborating with Vectura, or to arrange a meeting with Vectura's Business Development team, please contact:
Doug SmalleyBusiness Development and Licensing
Tel: +44 (0)1249 667700
Fax: +44 (0)1249 667701
Or please email your enquiry.
